Sirnaomics Advances STP705 for Squamous Cell Carcinoma In Situ into Late-Stage Clinical Development

Sirnaomics, a biopharmaceutical company focused on discovering and developing innovative drugs for indications with medical needs and large market opportunities, has announced the advancement of STP705 into late-stage clinical development for the treatment of Squamous Cell Carcinoma in situ (isSCC). The decision follows encouraging Phase IIa and Phase IIb clinical results that were shared with t..